Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts
Five years ago, OncoMed $OMED looked like one of the hottest oncology companies in the US, basking in the glow of a multibillion-dollar deal with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
